Green Light Therapy to Treat Migraine

Created on 11/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Green light therapy, a drug-free practice of sitting 1–2 hours in dim green lamp light, is used daily to prevent migraine or during an attack to ease it. Small studies suggest fewer headache days, less painful attacks and less headache-related disability, but the evidence is thin: participants mostly knew the light color, and much of it came from researchers with a financial stake. Risks are modest; it remains unproven. (Full Review)

Protocol

Preventive protocol (Arizona, Mohab Ibrahim)
525 nm, 4–100 lux, 1–2 h daily
Green LED strip 1–2 meters away, otherwise dark room, awake, light in the field of view, for 10 weeks
Acute protocol (Harvard, Rami Burstein; Allay Lamp)
520 ± 10 nm, 5–10 cd/m², 2 h per attack
Lamp 4–6 feet behind or above, during an attack, with all other light off
Short-course protocol (Pakistan)
525 ± 10 nm, 1 h daily, 5 days a week
Lamp sessions for four weeks, daytime, alongside usual medication
Time to effect
Fewer monthly headache days
Over 10 weeks
Assessment period of the Arizona trial; response commonly judged at 10–12 weeks
Lower headache pain intensity
By two weeks
Pain differences appeared in the Pakistani trial
Relief during an ongoing attack
Within two hours
Acute use judged within the two-hour lamp session

Benefits

Contraindications
  • People whose attack headache intensifies under green light
  • People within 30 days of porfimer (Photofrin) dosing, for any bright or close-range lamp
  • People with photosensitive epilepsy using lamps that flicker (inferred; no human data with therapy lamps)
Key Interactions
Theoretical (inferred from mechanism)
  • Triptans and over-the-counter pain relievers (sumatriptan, ibuprofen): waiting out a two-hour lamp session may lower the chance of attack relief
  • Drugs that impair color vision or retinal function (ethambutol, hydroxychloroquine): may blunt benefit
  • Sunlight-photosensitizing drugs (doxycycline, hydrochlorothiazide): no consequence is expected
  • St John's wort: possible skin or eye irritation at close range
  • Melatonin supplements: evening sessions may partly offset a melatonin dose
  • Migraine-preventive supplements (magnesium, riboflavin): additive preventive effect; any added benefit is untested
  • Other light treatments (bright white light boxes): opposing effect
  • Transcranial direct current stimulation: additive effect on pain processing

Risk & Side Effects

  • High:
  • Medium: Headache worsening during light exposure
  • Low: Reduced effect of delayed acute medication; evening melatonin suppression; visual discomfort from the light
  • Speculative: Seizure provocation by flickering sources; retinal light injury at high intensity

Monitoring

Marker Target Why
Monthly headache days No established target; track change from own baseline Expected to change
Attack pain (0–10 numeric pain scale) No established target; track change from own baseline Expected to change; a rise during a session is a safety check
Headache Impact Test-6 (HIT-6) score No established target; track change from own baseline Expected to change
Acute medication days per month No established target; track change from own baseline Expected to change; shows whether attack treatment was delayed

Cadence: Baseline headache diary for at least four weeks; diary daily, pain rated at the start and end of each session; summary measures compared with baseline at 4 weeks, at 10–12 weeks, then every 3 months while use continues. No blood test is needed.

Qualitative Assessment

  • Light sensitivity during and between attacks
  • Sleep onset and continuity on session days
  • Anxiety and calm during attacks
  • Ability to work and perform daily activities
  • Adherence: sessions completed per week